Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis

Novel approaches to the treatment ofPseudomonas aeruginosainfections in cystic fibrosis

“…While there have been some clinical trials of vaccine preparations published suggesting a positive effect, few are of high quality in terms of randomisation and design. Three of these trials were included in a Cochrane review involving 996 patients with a follow-up of between two and twelve years where the authors concluded that vaccination cannot currently be recommended[99].…”

“…However the authors of the currently available studies suggest that Immunoglobulin Y (IgY) prophylaxis could increase the time to first infection, reduce the number of infection events, reduce the time to established chronic infection and delay the conversion to a mucoid strain[100]. These results have prompted its licensing in Sweden[99] and its designation as an orphan drug. A Phase III double blind randomised controlled trial of 180 patients is underway (Clinicaltrial.gov identifier NCT01455675) recruiting those with P. aeruginosa infection with the primary outcome measure being time from start of treatment to the first isolation of P. aeruginosa from sputum culture or throat swab.…”

Novel approaches to the treatment ofPseudomonas aeruginosainfections in cystic fibrosis

“…While there have been some clinical trials of vaccine preparations published suggesting a positive effect, few are of high quality in terms of randomisation and design. Three of these trials were included in a Cochrane review involving 996 patients with a follow-up of between two and twelve years where the authors concluded that vaccination cannot currently be recommended[99].…”

“…However the authors of the currently available studies suggest that Immunoglobulin Y (IgY) prophylaxis could increase the time to first infection, reduce the number of infection events, reduce the time to established chronic infection and delay the conversion to a mucoid strain[100]. These results have prompted its licensing in Sweden[99] and its designation as an orphan drug. A Phase III double blind randomised controlled trial of 180 patients is underway (Clinicaltrial.gov identifier NCT01455675) recruiting those with P. aeruginosa infection with the primary outcome measure being time from start of treatment to the first isolation of P. aeruginosa from sputum culture or throat swab.…”

Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis

“…Attempts to develop clinically efficacious vaccines against P. aeruginosa have, to date, been unsuccessful [88]. Obstacles include P. aeruginosa's multiple antigenic determinants, multiple serotypes of these determinants between clinical strains and the different expression of determinants under different conditions (e.g.…”

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

“……”

Novel approaches to the treatment ofPseudomonas aeruginosainfections in cystic fibrosis

“…While there have been some clinical trials of vaccine preparations published suggesting a positive effect, few are of high quality in terms of randomisation and design. Three of these trials were included in a Cochrane review involving 996 patients with a follow-up of between two and twelve years where the authors concluded that vaccination cannot currently be recommended[99].…”

“…However the authors of the currently available studies suggest that Immunoglobulin Y (IgY) prophylaxis could increase the time to first infection, reduce the number of infection events, reduce the time to established chronic infection and delay the conversion to a mucoid strain[100]. These results have prompted its licensing in Sweden[99] and its designation as an orphan drug. A Phase III double blind randomised controlled trial of 180 patients is underway (Clinicaltrial.gov identifier NCT01455675) recruiting those with P. aeruginosa infection with the primary outcome measure being time from start of treatment to the first isolation of P. aeruginosa from sputum culture or throat swab.…”

Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis

“…Attempts to develop clinically efficacious vaccines against P. aeruginosa have, to date, been unsuccessful [88]. Obstacles include P. aeruginosa's multiple antigenic determinants, multiple serotypes of these determinants between clinical strains and the different expression of determinants under different conditions (e.g.…”

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

“……”

Novel approaches to the treatment ofPseudomonas aeruginosainfections in cystic fibrosis

“…While there have been some clinical trials of vaccine preparations published suggesting a positive effect, few are of high quality in terms of randomisation and design. Three of these trials were included in a Cochrane review involving 996 patients with a follow-up of between two and twelve years where the authors concluded that vaccination cannot currently be recommended[99].…”

“…However the authors of the currently available studies suggest that Immunoglobulin Y (IgY) prophylaxis could increase the time to first infection, reduce the number of infection events, reduce the time to established chronic infection and delay the conversion to a mucoid strain[100]. These results have prompted its licensing in Sweden[99] and its designation as an orphan drug. A Phase III double blind randomised controlled trial of 180 patients is underway (Clinicaltrial.gov identifier NCT01455675) recruiting those with P. aeruginosa infection with the primary outcome measure being time from start of treatment to the first isolation of P. aeruginosa from sputum culture or throat swab.…”

Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis

“…Attempts to develop clinically efficacious vaccines against P. aeruginosa have, to date, been unsuccessful [88]. Obstacles include P. aeruginosa's multiple antigenic determinants, multiple serotypes of these determinants between clinical strains and the different expression of determinants under different conditions (e.g.…”

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

“……”